Press release


GeNeuro Announces Approval of all Resolutions
Proposed at Extraordinary General Meeting
▪ 69.1% of the Company’s share capital was represented at the EGM and resolutions
were all unanimously approved

Geneva, Switzerland, June 30, 2025 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 -
GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and
autoimmune diseases, announces that its shareholders have approved all resolutions proposed at its
Extraordinary General Meeting (EGM) of 30 June 2025.

69.1% of the Company’s share capital was present or represented at the EGM and resolutions were all
unanimously approved. Detailed results will be available on the Company’s website at:
http://www.geneuro.com/en/investors/general-meetings.

As mentioned in the invitation to the EGM, in order to ensure continuity of governance, this
Extraordinary General Meeting had been called to vote on the re-election of the members of the Board
of Directors, the Chairman of the Board of Directors and the Remuneration Committee, as well as the
independent representative, until the next Ordinary General Meeting can be held. Following his re-
election to the Board, Mr Jesús Martin-Garcia has been named Executive Chairman of the Company.

As previously announced, following the disappointing results of its last Phase 2 clinical trial in Long
COVID, the Company has launched a major restructuring, making redundant all employees at the
parent company level, seeking and obtaining a debt-restructuring moratorium and launching a major
effort to monetize its assets. Despite the end of their employment contract at the end of December
2024, both Jesús Martin-Garcia and Mr Miguel Payró have agreed to continue on a part-time basis to
support the Company’s efforts as Executive Chairman and Chief Financial Officer respectively. As for
the 2024 financial statements, in view of the uncertainty surrounding the outcome of the asset
monetization process, the Company had announced that it suspended publication of its financial
statements.



About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune
diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of
human DNA. For more information, visit: www.geneuro.com




Contacts:

GeNeuro

Jesús Martin-Garcia
Chairman and CEO
investors@geneuro.com



Disclaimer:
This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial
condition, operating results, strategy, projects and future performance and the markets in which it operates. Such
forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,”
“estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or

1
the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward
looking statements, forecasts and estimates are based on management’s current assumptions and assessment of
risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they
were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on
factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or
achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances
or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties,
no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and
estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which
they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new
information, future events or otherwise, except as required by law.




2